TY - JOUR
T1 - The Efficacy of Plasma Rich in Growth Factors for the Treatment of Alveolar Osteitis
T2 - A Randomized Controlled Trial
AU - King, Elizabeth M.
AU - Cerajewska, Tanya L.
AU - Locke, Matthew
AU - Claydon, Nicholas C.A.
AU - Davies, Maria
AU - West, Nicola X.
PY - 2018/1/8
Y1 - 2018/1/8
N2 - Purpose: To investigate the efficacy of plasma rich in
growth factors (PRGF)® for the treatment of alveolar osteitis compared to a
positive control Alvogyl®.
Methods: This single centre, single blind, randomised, two
treatment, parallel study was conducted in a UK dental hospital. All healthy
adults who presented with alveolar osteitis following tooth extraction over a 3
month period were invited to participate. Each socket was randomised and
treated with one of two treatment modalities, a test treatment PRGF® or a
positive control Alvogyl®. Following treatment, patients were reviewed at 3 and
7 days by a second clinician blinded to the treatment given. Outcome measures included
pain, exposed bone, inflammation, halitosis, dysgeusia and quality of life
assessment.
Results: 38 patients with data from 44 sockets, 22 in the
PRGF® group and 22 in the Alvogyl® group, were analysed. The PRGF® group
demonstrated significantly faster bone coverage as well as significantly
reduced inflammation and halitosis (p<0.05) compared to the control group
receiving Alvogyl®. There was no significant difference for pain, quality of
life measures or dysgeusia between the groups.
Conclusion: PRGF® predictably treated alveolar osteitis
following tooth extraction compared to the conventional standard treatment of
Alvogyl® which has been used for many years. PRGF could be considered as an
alternative treatment for alveolar osteitis, and indeed appears to have
significant advantages over Alvogel®.
AB - Purpose: To investigate the efficacy of plasma rich in
growth factors (PRGF)® for the treatment of alveolar osteitis compared to a
positive control Alvogyl®.
Methods: This single centre, single blind, randomised, two
treatment, parallel study was conducted in a UK dental hospital. All healthy
adults who presented with alveolar osteitis following tooth extraction over a 3
month period were invited to participate. Each socket was randomised and
treated with one of two treatment modalities, a test treatment PRGF® or a
positive control Alvogyl®. Following treatment, patients were reviewed at 3 and
7 days by a second clinician blinded to the treatment given. Outcome measures included
pain, exposed bone, inflammation, halitosis, dysgeusia and quality of life
assessment.
Results: 38 patients with data from 44 sockets, 22 in the
PRGF® group and 22 in the Alvogyl® group, were analysed. The PRGF® group
demonstrated significantly faster bone coverage as well as significantly
reduced inflammation and halitosis (p<0.05) compared to the control group
receiving Alvogyl®. There was no significant difference for pain, quality of
life measures or dysgeusia between the groups.
Conclusion: PRGF® predictably treated alveolar osteitis
following tooth extraction compared to the conventional standard treatment of
Alvogyl® which has been used for many years. PRGF could be considered as an
alternative treatment for alveolar osteitis, and indeed appears to have
significant advantages over Alvogel®.
KW - alveolar osteitis
KW - plasma rich in growth factors
KW - alvogyl
KW - bone healing
KW - PRGF
UR - http://www.scopus.com/inward/record.url?scp=85042176110&partnerID=8YFLogxK
U2 - 10.1016/j.joms.2017.12.025
DO - 10.1016/j.joms.2017.12.025
M3 - Article (Academic Journal)
C2 - 29382467
AN - SCOPUS:85042176110
SN - 0278-2391
JO - Journal of Oral and Maxillofacial Surgery
JF - Journal of Oral and Maxillofacial Surgery
ER -
